ImpediMed Limited (ASX:IPD – Get Free Report) insider Andrew Grant purchased 600,000 shares of the business’s stock in a transaction on Thursday, September 5th. The stock was purchased at an average cost of A$0.05 ($0.03) per share, for a total transaction of A$28,800.00 ($19,200.00).
Andrew Grant also recently made the following trade(s):
- On Friday, August 30th, Andrew Grant bought 1,000,000 shares of ImpediMed stock. The shares were acquired at an average price of A$0.05 ($0.03) per share, for a total transaction of A$50,000.00 ($33,333.33).
ImpediMed Price Performance
The company has a debt-to-equity ratio of 2.50, a quick ratio of 6.23 and a current ratio of 7.00.
About ImpediMed
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.
Featured Articles
- Five stocks we like better than ImpediMed
- Canadian Penny Stocks: Can They Make You Rich?
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Business Services Stocks Investing
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for ImpediMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImpediMed and related companies with MarketBeat.com's FREE daily email newsletter.
